Mexican plants for supplies, medicines and medical devices They have tripled their production to face the COVID-19 pandemic, Rafael Gual, director general of the National Chamber of the Pharmaceutical Industry (Canifarma), said on Friday.
"The pharmaceutical industry is working 100%, including doubling and tripling shifts in some cases, especially in the part of medical devices, in order to alleviate these needs that are occurring extraordinarily"Gual commented in an interview with EFE.
The more than 160 companies grouped in the Canifarma, representing 1% of GDP, 100,000 direct jobs and 500,000 indirect jobs, They have even hired more personnel, Gual declared without specifying the number.
In the midst of the crisis, the Canifarma representative predicted growth in the sector of up to 7% in Mexico, the eighth largest producer of medical equipment worldwide and the first in Latin America, with an average annual investment of 38,000 million pesos (USD 1,670 million).
Even so, the industry has also faced challenges due to global disruption caused by the new coronavirus, Gual warned.
"The challenges are many. We have faced many adverse conditions, since the acquisition of active ingredients that have to be acquired in the world, not many of them are manufactured in Mexico and, given this situation, this value chain has been cut short, "he said.
SOLIDARITY IN THE EMERGENCY
Canifarma has launched an extraordinary emergency fund to deal with the COVID-19 pandemic, which accumulates 62,527 infections and 6,989 confirmed deaths in Mexico.
So far they have contributed with more than 210 million pesos (USD 9.2 million), said Gual.
In addition, companies They have donated 153 respirators, 1.4 million pieces of protective equipment, more than 2,000 liters of antibacterial gel and more than 5,000 medications and tests. tests for patients with COVID-19.
"The pharmaceutical industry is doing its important work, trying to cover all the supply of medicines that are required in the country in these complicated conditions, but with that conviction that the supply of medicines is the main function of the industry, "said Gual.
The executive stated that Canifarma works to guarantee supply in the most critical phase of COVID-19 in the country, with a 39% of hospital occupancy nationwide and 34% of beds with ventilators.
Despite the official program of economic revival towards "a new normal", which started partially this week, the industry leader said prepared for the extension of the pandemic.
"We are thinking that it will still take a few more months, but in the end, I insist, the industry will continue to work within the 'new normal', one hundred percent, "he said.
Canifarma companies are mainly concentrated in the State of Mexico, Jalisco, Mexico City, Puebla and Aguascalientes, some of them in the areas most affected by the pandemic.
MORE ABOUT OTHER TOPICS:
"His is not a free market, it is theft": Bartlett attacked renewable energy companies
Government backed down and allowed wind and solar plants to test in Mexico after a rain of amparos
"We will use all legal means to prevent it": Tamaulipas goes against the brakes for renewables